BridgeBio, Pfizer
BridgeBio Wins FDA Approval for ATTR-CM Drug, Launching Competition With Pfizer
BridgeBio secured approval for Attruby Friday, along with the all-important mortality benefit that could give the drug a significant boost in the market against Pfizer’s tafamidis and potentially Alnylam’s Amvuttra.
The pharma leader is betting that streamlined services may be a shot in the arm for Americans seeking care with its ...
Pfizer has named company veteran Chris Boshoff, who led the drugmaker's cancer research and marketing for more than a year, ...
Pfizer, despite pressure from investors to look outside, elevates its cancer chief Chris Boshoff to lead overall R&D.
Is Pfizer stock a sell after shares skidded on the news Trump selected Kennedy to take over HHS? Is PFE stock now a sell?
4don MSN
Company veteran Chris Boshoff, who has led Pfizer’s cancer research and marketing for more than a year, will become chief ...
Pfizer shares are trading lower by 10% in November. President-elect Donald Trump last week announced his intention to nominate Robert F. Kennedy Jr. to lead the HHS.
Pfizer, a multinational pharmaceutical and biotechnology corporation, is now a $159 billion (by market cap) healthcare giant.
No financial details of the collaborations were released. However, Pfizer and Flagship committed $50 million each for the ...
Meta Platforms Inc, Pfizer Inc and American Airlines are among the companies the Labor Department’s contractor watchdog has ...
Bourla said in a statement that Boshoff was “the ideal leader to propel Pfizer’s R&D engine forward and transform it into a world-leading organisation with a more focused strategy, driving the ...
Pfizer has found a successor for Chief Scientific Officer and R&D head Mikael Dolsten, M.D., Ph.D., tapping the company’s own ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback